Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Panel Votes to Recommend Dynavax’s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline’s Engerix-B

A U.S. Food and Drug Administration advisory committee gave a thumb’s-up recommendation for Dynavax Technologies Corporation’s Heplisav-B hepatitis B vaccine.

Read More »

AbbVie’s profit beats analysts’ expectations

U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.

Read More »

CMOs Cringe as GlaxoSmithKline Will be Cutting Its Use by 25%

GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.

Read More »

Bristol-Myers shares slump after rival’s failed study

Bristol-Myers Squibb shares fell as a failed cancer-drug trial at AstraZeneca could have negative implications for its similar immunotherapy treatment regimen.

Read More »

Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma

While reporting strong earnings, New Haven, Conn.-based Alexion Pharmaceuticals also indicated the company plans to retool its research-and-development strategy.

Read More »

AstraZeneca lung cancer failure sparks share fall

AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.

Read More »

GlaxoSmithKline’s new boss streamlines R&D

GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.

Read More »

Eli Lilly Shakes Up Cancer R&D Strategy

Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.

Read More »

Ironwood’s Potential Blockbuster Drug Meets Main Goals in Mid-Stage Trial

Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.

Read More »

Novartis Boss Updates Q2 2017 Financials, Reaffirms M&A Strategy

Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom